Skip to main content

Muscle Atrophy

3
Pipeline Programs
3
Companies
5
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
1
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Oregon Therapeutics
Oregon TherapeuticsFrance - Paris
2 programs
1
1
TestosteronePhase 31 trial
Essential Amino AcidsPhase 21 trial
Active Trials
NCT02145949Completed80Est. Feb 2020
NCT01595581Completed14Est. May 2015
Immunis
ImmunisCA - Irvine
1 program
1
IMM01-STEMPhase 1/21 trial
Active Trials
NCT05211986Recruiting28Est. Jun 2026
Human BioSciences
Human BioSciencesWV - Martinsburg
2 programs
Physical TherapyN/A1 trial
RENEWN/A1 trial
Active Trials
NCT00060970Completed30Est. Aug 2000
NCT01080196Completed134Est. Feb 2014

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Oregon TherapeuticsTestosterone
Oregon TherapeuticsEssential Amino Acids
ImmunisIMM01-STEM
Human BioSciencesRENEW
Human BioSciencesPhysical Therapy

Clinical Trials (5)

Total enrollment: 286 patients across 5 trials

NCT01595581Oregon TherapeuticsTestosterone

Testosterone Administration and ACL Reconstruction in Men

Start: Apr 2012Est. completion: May 201514 patients
Phase 3Completed
NCT02145949Oregon TherapeuticsEssential Amino Acids

Mechanistic Approach to Preventing Atrophy and Restoring Function in Older Adults

Start: Dec 2014Est. completion: Feb 202080 patients
Phase 2Completed
NCT05211986ImmunisIMM01-STEM

Safety and Tolerability of IMM01-STEM in Patients With Muscle Atrophy Related to Knee Osteoarthritis.

Start: Sep 2022Est. completion: Jun 202628 patients
Phase 1/2Recruiting
NCT01080196Human BioSciencesRENEW

Reducing Falls With RENEW in Older Adults Who Have Fallen

Start: Apr 2008Est. completion: Feb 2014134 patients
N/ACompleted
NCT00060970Human BioSciencesPhysical Therapy

Evaluating Muscle Function After Ankle Surgery

Start: Sep 1995Est. completion: Aug 200030 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 286 patients
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.